{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-006441","form_type":"8-K/A","ticker":"XBIT","cik":"0001626878","company_name":"XBiotech Inc.","filed_at":"2025-10-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.970946+00:00","generated_at":"2026-05-17T03:44:25.589019+00:00","sec_items":["5.02"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"XBiotech amends director bio: Rademaker is consultant to multiple PE firms","bullets":["Clarifies Craig Rademaker is a consultant to several Canadian private equity firms, not a single firm.","His responsibilities principally include capital markets activities.","No change to his role as director or any compensatory arrangements.","Amendment corrects prior 8-K filed June 24, 2025, for Item 5.02."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-006441","json":"https://secwatch.observer/filing/0001171843-25-006441.json","markdown":"https://secwatch.observer/filing/0001171843-25-006441.md","text":"https://secwatch.observer/filing/0001171843-25-006441.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626878/000117184325006441/0001171843-25-006441-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626878/000117184325006441/f8ka_101525.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:44:25.589019+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}